Liraglutide vs LL-37 (Cathelicidin)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Liraglutide
Liraglutide is a GLP-1 receptor agonist — a 31-amino acid peptide analog with 97% homology to native human GLP-1. FDA-approved for type 2 diabetes (Victoza, 2010) and chronic weight management (Saxenda, 2014). It was the first GLP-1 agonist approved specifically for obesity. Liraglutide has a shorter half-life than semaglutide (13 hours vs 7 days), requiring daily rather than weekly dosing.
Full details →LL-37 (Cathelicidin)
LL-37 is the only human cathelicidin antimicrobial peptide. It plays crucial roles in innate immunity and has shown diverse biological activities including antimicrobial, immunomodulatory, and wound healing properties.
Full details →Side-by-Side Comparison
| Aspect | Liraglutide | LL-37 (Cathelicidin) |
|---|---|---|
| Mechanism | Liraglutide binds to the GLP-1 receptor, activating the same pathways as native GLP-1: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite suppression. A C-16 fatty acid (palmitic acid) attached to Lys26 via a glutamic acid spacer enables albumin binding, extending the half-life from ~2 minutes (native GLP-1) to ~13 hours. Less potent albumin binding and shorter half-life compared to semaglutide necessitates once-daily dosing. | Disrupts bacterial membranes, neutralizes endotoxins, modulates immune cell function, and promotes wound healing. Has both direct antimicrobial and immunomodulatory effects. |
| Typical Dosage | For weight management (Saxenda): start at 0.6 mg daily for 1 week. Increase by 0.6 mg weekly until reaching 3.0 mg daily maintenance dose. For type 2 diabetes (Victoza): start at 0.6 mg daily for 1 week, increase to 1.2 mg. May increase to 1.8 mg if additional glycemic control is needed. | Research protocols vary widely. Typical ranges: 50-200mcg administered subcutaneously 2-3 times weekly. Some protocols use higher doses for acute infections. |
| Administration | Subcutaneous injection in the abdomen, thigh, or upper arm. Rotate injection sites. Administer once daily at any time, independent of meals. Store pens refrigerated before first use; after first use, store at room temperature or refrigerated for up to 30 days. | Subcutaneous injection. Can cause significant injection site reactions. Often used in conjunction with other immune-supporting protocols. |
| Side Effects | Very common (>10%): nausea (up to 40%), diarrhea, constipation, vomiting, decreased appetite, dyspepsia, abdominal pain. Higher rate of daily GI symptoms compared to weekly GLP-1s due to daily dosing peaks. Common (1-10%): headache, dizziness, fatigue, injection site reactions, increased heart rate. | Injection site pain and reactions are common. May cause flu-like symptoms, temporary fatigue, or immune activation responses. |
| Best For |
Key Differences
Unique to Liraglutide:
Unique to LL-37 (Cathelicidin):
Detailed Analysis
Commonalities
LL-37 (Cathelicidin) and Liraglutide are used for different purposes and have limited overlap in their applications.
Which Should You Choose?
Choose LL-37 (Cathelicidin) for Recovery & Healing. Choose Liraglutide for Fat Loss.
Ready to Learn More?
Looking for trusted sources?